Lupin gets USFDA approval for hypertension pills

Pharma major Lupin Wednesday said it has got approval from the US Food and Drugs Administration (FDA) to market generic versions of Sanofi Aventis’ Avapro tablets, prescribed in the treatment of hypertension and nephropathy in Type-II diabetis.

Lupin in a release said its wholly-owned subsidiary Lupin Pharmaceuticals Inc. has received the FDA nod for its Irbesartan tablets, the generic versions of Sanofi’s 75, 150 and 300 mg Avapro tablets.

[caption id=“attachment_493678” align=“alignleft” width=“380”]  Agencies[/caption]

Lupin, the third largest Indian pharmaceutical company by sales, is the fifth largest and fastest growing generics player in the US. Avapro tablets had annual US sales of approximately $400.7 million.

More from Business fwire

China property sector distress deepens as second company runs into financial troubles Labour codes unlikely to be implemented this fiscal due to slow progress on drafting of rules, political considerations

The city-based company is producing and developing a wide range of branded and generic formulations and APIs (active pharmaceutical ingredients). It is a significant player in the asthma, cardiovascular, diabetology and pediatric space and holds global leadership positions in the anti-TB and cephalosporin segment.

In the last fiscal, Lupin’s consolidated total income and profit after tax were Rs.70,972 million ($1.49 billion) and Rs.8,676 million ($182 million) respectively.

IANS